

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 June 2023 (01.06.2023)



(10) International Publication Number
WO 2023/097291 A1

(51) International Patent Classification:

C12N 15/11 (2006.01) C07H 21/04 (2006.01)
C12N 15/113 (2010.01) C07H 19/167 (2006.01)
A61K 31/713 (2006.01) C07H 21/02 (2006.01)

(21) International Application Number:

PCT/US2022/080448

(22) International Filing Date:

23 November 2022 (23.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/283,177	24 November 2021 (24.11.2021)	US
63/287,952	09 December 2021 (09.12.2021)	US
63/302,976	25 January 2022 (25.01.2022)	US
63/339,873	09 May 2022 (09.05.2022)	US

(71) Applicant: ADARX PHARMACEUTICALS, INC.

[US/US]; 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(72) Inventors: LI, Zhen; c/o Adarx Pharmaceuticals, Inc.,

5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). ZHU, Rui; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). ZHOU, Zhiqing (Joel); c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). STUDER, Sean; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). FULTZ, Kimberly; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). CORREIA, Jean, Da Silva; c/o Adarx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(74) Agent: BOWLER, Joseph, M. et al.; Wolf, Greenfield &

Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPLEMENT FACTOR B-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Complement Factor B (CFB). In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB mRNA in a cell or animal. In certain aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of CFB protein in a cell or animal.

WO 2023/097291 A1